Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Convertible Debt (2021 - 2026)

Bioceres Crop Solutions' Convertible Debt history spans 6 years, with the latest figure at $108.3 million for Q1 2026.

  • On a quarterly basis, Convertible Debt changed N/A to $108.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $108.3 million, a N/A change, with the full-year FY2025 number at $102.3 million, up 26.59% from a year prior.
  • Convertible Debt hit $108.3 million in Q1 2026 for Bioceres Crop Solutions, up from $102.3 million in the prior quarter.
  • Over the last five years, Convertible Debt for BIOX hit a ceiling of $108.3 million in Q1 2026 and a floor of $12.6 million in Q2 2022.
  • Historically, Convertible Debt has averaged $75.8 million across 5 years, with a median of $80.8 million in 2024.
  • Biggest five-year swings in Convertible Debt: crashed 74.19% in 2022 and later skyrocketed 498.88% in 2023.
  • Tracing BIOX's Convertible Debt over 5 years: stood at $12.6 million in 2022, then skyrocketed by 498.88% to $75.2 million in 2023, then increased by 7.44% to $80.8 million in 2024, then increased by 26.59% to $102.3 million in 2025, then grew by 5.87% to $108.3 million in 2026.
  • Business Quant data shows Convertible Debt for BIOX at $108.3 million in Q1 2026, $102.3 million in Q2 2025, and $80.8 million in Q2 2024.